Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (11): 827-833.DOI: 10.5246/jcps.2017.11.093

• Original articles • Previous Articles     Next Articles

Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

Daiying Zhou1, Li Ding1, Xi Wang1*, Juan Ma1, Wolin Huang1, Susan Goodin2, Xi Zheng3*   

  1. 1. Guangdong Food and Drug Vocational College, Guangzhou 510520, China
    2. Rutgers Cancer Institute of New Jersey, USA
    3. Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, USA
  • Received:2017-07-18 Revised:2017-10-16 Online:2017-11-30 Published:2017-10-27
  • Contact: Tel.: +732-445-3400(233); +86-020-28854939, Fax: +732-445-0687; +86-020-37216565, E-mail:;
  • Supported by:

    The National Cancer Institute of China (Grant No. P30-CA072720), the National Natural Science Foundation of China (Grant No. 81272452), and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (Grant No. 2014A030310329).


Cancer of the prostate gland is a leading cause of death. In the present study, we studied the effects and mechanisms of curcumin analogue E10, docetaxel or their combination on prostate cancer (PC)-3 cells. Treatment of PC-3 cells with E10 or docetaxel resulted in growth inhibition in a concentration-reliant fashion. Combinations of E10 and docetaxel inhibited the growth of PC-3 cells in a synergistic manner. Effects of a combination of E10 and docetaxel were associated with synergistic inhibition of the transcriptional activity of nuclear factor-kappa B (NF-κB), and robust reductions in the levels of B-cell lymphoma-2 (Bcl-2) were found in PC-3 cells treated with a combination of E10 and docetaxel. Our data indicated that the effects of E10 in combination with docetaxel on PC-3 cells were associated with inhibition of NF-κB and Bcl-2. Further studies using suitable animal models are necessary to determine the in vivo effect of this combination. 

Key words: Combination treatment, Prostate cancer, Curcumin analogue, Docetaxel, Synergistic effect

CLC Number: